Ftse Mib
35.410,13
0,12%
DAX
18.738,81
-0,72%
S&P 500
5.297,10
-0,21%
NASDAQ
16.698,32
-0,26%
Bitcoin
65.121,52
-0,18%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Eagle Pharmaceuticals Inc (EGRX) Eagle Pharmaceuticals Inc (EGRX) Notizie

EGRX

Eagle Pharmaceuticals (EGRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EGRX
DataOraFonteTitoloSimboloCompagnia
15/05/202415:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EGRXEagle Pharmaceuticals Inc
10/05/202423:27Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:EGRXEagle Pharmaceuticals Inc
01/03/202422:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EGRXEagle Pharmaceuticals Inc
14/02/202423:09Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:EGRXEagle Pharmaceuticals Inc
13/02/202421:53Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EGRXEagle Pharmaceuticals Inc
12/02/202419:38Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:EGRXEagle Pharmaceuticals Inc
09/02/202411:45PR Newswire (US)Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRXNASDAQ:EGRXEagle Pharmaceuticals Inc
02/02/202411:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX)NASDAQ:EGRXEagle Pharmaceuticals Inc
18/01/202412:50GlobeNewswire Inc.Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property PortfolioNASDAQ:EGRXEagle Pharmaceuticals Inc
22/12/202323:15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:EGRXEagle Pharmaceuticals Inc
06/12/202322:05GlobeNewswire Inc.Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York CityNASDAQ:EGRXEagle Pharmaceuticals Inc
09/11/202313:30GlobeNewswire Inc.Eagle Delays Third Quarter 2023 Results and Conference CallNASDAQ:EGRXEagle Pharmaceuticals Inc
08/11/202314:30GlobeNewswire Inc.Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023NASDAQ:EGRXEagle Pharmaceuticals Inc
02/11/202321:53Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EGRXEagle Pharmaceuticals Inc
24/10/202314:40GlobeNewswire Inc.Eagle Pharmaceuticals Granted Patent for PEMFEXY®NASDAQ:EGRXEagle Pharmaceuticals Inc
23/10/202312:50GlobeNewswire Inc.Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMSNASDAQ:EGRXEagle Pharmaceuticals Inc
04/10/202312:50GlobeNewswire Inc.Eagle Pharmaceuticals Awarded First Prize for Poster to Be Presented at the International Society for Anaesthetic Pharmacology 32nd Annual MeetingNASDAQ:EGRXEagle Pharmaceuticals Inc
19/09/202322:05GlobeNewswire Inc.Eagle Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023NASDAQ:EGRXEagle Pharmaceuticals Inc
11/09/202312:50GlobeNewswire Inc.Eagle Pharmaceuticals to Present CAL02 Trial in Progress at the 2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial ResistanceNASDAQ:EGRXEagle Pharmaceuticals Inc
30/08/202312:50GlobeNewswire Inc.Eagle Pharmaceuticals to Present BYFAVO® (remimazolam) for Injection Abstract at Prestigious Society for Neuroscience in Anesthesiology and Critical Care (SNACC) ConferenceNASDAQ:EGRXEagle Pharmaceuticals Inc
29/08/202312:50GlobeNewswire Inc.Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal WomenNASDAQ:EGRXEagle Pharmaceuticals Inc
22/08/202322:05GlobeNewswire Inc.Eagle Pharmaceuticals to Present at Two Upcoming Healthcare ConferencesNASDAQ:EGRXEagle Pharmaceuticals Inc
17/08/202312:50GlobeNewswire Inc.Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP E¹ GuidanceNASDAQ:EGRXEagle Pharmaceuticals Inc
09/08/202322:17Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:EGRXEagle Pharmaceuticals Inc
08/08/202322:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EGRXEagle Pharmaceuticals Inc
08/08/202312:50GlobeNewswire Inc.Eagle Pharmaceuticals Reports Second Quarter 2023 ResultsNASDAQ:EGRXEagle Pharmaceuticals Inc
01/08/202312:50GlobeNewswire Inc.Eagle Pharmaceuticals to Host Second Quarter 2023 Financial Results on August 8, 2023NASDAQ:EGRXEagle Pharmaceuticals Inc
31/07/202312:50GlobeNewswire Inc.Eagle Pharmaceuticals Raises 2023 Adjusted non-GAAP EPS¹ GuidanceNASDAQ:EGRXEagle Pharmaceuticals Inc
24/07/202312:50GlobeNewswire Inc.Eagle Pharmaceuticals Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)NASDAQ:EGRXEagle Pharmaceuticals Inc
15/06/202313:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:EGRXEagle Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EGRX

La tua Cronologia

BIT
ENI
Eni
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BPE
Bper Banca
BIT
SRG
Snam
BIT
LDO
Leonardo
BIT
RACE
Ferrari NV
BIT
TIT
Telecom Italia
BIT
STMMI
ST Microelectronics
BIT
BAMI
Banco BPM
BIT
ELN
ElEn
BIT
FBK
Finecobank
BIT
PRY
Prysmian
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network